proprietary is life-threatening in blood unit such dialysis, found cardiac quarter our that and blood afternoon, heart-lung the technology. single-use the intensive ECMO hospitals welcome, our today, the treatment XXXX through machines. with of and bead of to conditions you Thank Adanna, in very filled surgery plug-and-play beads and these high-margin earnings as are in with existing pump sorbent CytoSorbents call. leader Cartridges much, machines disposables are removal with third care from compatible blood purification and a harmful substances good the everyone, and
broad applications. Our a in technologies are of used blood number purification
the blood Specifically, agents and two, of during critical removal surgery. after of X and illnesses are: the cardiothoracic applications as such common thinners removal sepsis; important in one, inflammatory
Our million in flagship product, CytoSorb, in European $XX is surgery, conditions as unit to sepsis treat million intensive $XX life-threatening generates million and in failure, the Union care liver approved such primarily is the across to trailing cardiac with and worldwide. sales roughly in high-margin growing, quarter, as million end sales of more annual than $XX devices XX-month X.XX the third cumulatively about used to in of the date countries with XX
medical product to designed is DrugSorb the bleeding drugs. investigational severity urgent cardiac thinning ATR, of second surgery Our by device perioperative blood removing an reduce during
highlighting need. this designations have application, breakthrough X for We FDA device significant received medical unmet the
on eliminating goal XXXX. with treatment data hospital marketing pivotal on consume safe CABG risk Now drug and and delays to undergoing from enable thinning for patients to timely based Canadian applied randomized Canada Brilinta, CABG and FDA while surgery U.S. the decisions have now STAR-T, expose our we U.S. Health and additional in controlled in surgery both approval The regulatory to trial blood that patients expected resources. is valuable
perhaps prepared core in set clinical most solid bring discuss addressable continued real-world an growth phase of our in well reaching this I foundation initial will time. ATR progress launch I positioned in and with over each grow aspects market therapies, believe top believe over operating well and next our quarter $X TAM in including or we regulatory you'll million are milestones we our to my am of which of growth future $XXX made market, in international support the to see our business, that billion a performance, American and pleased that of DrugSorb efficiencies, North business, line process importantly, to significant of represent total for CytoSorb year-to-date remarks, key we the of I and the improvements our across to evidence ongoing these could could development success.
Chief Pete new few detail a is But Mariani, off will and Our to Financial points. provide performance. let on our me fast more detail Officer, a start financial key
were in year-over-year, $X.X First, range million million international sales and our QX product million, Germany guided growth in of our and direct and by served representing in sales our geographies a to network. distributor interest in channels reflecting above XXXX CytoSorb $X.X previously strength $X.X internationally XX% growing
of XX% number our reflected lower of a due quarter, were margins down CytoSorb third quarter, but XX%, gross the for XX% above as the quarter. rebalance XX% well short-term the production during manufacturing a produced a planned devices inventory to in significantly range in Product to This previously resolved that levels slowdown guided we to as year-over-year. issue
production levels gross product margins quarter. normalized in more current the to return to and expect We
to the to in XX% decreased our Canada pending expenses next for demonstrate expansion $X.X year, America our approach clearances. operating the allowing therapies, driving cash management, opportunistic us DrugSorb our and Health of year. to lowering year-over-year, reduction prepare million Operating disciplined in burn our million quarter savings approximately These second FDA into launch expected XX% to additional in geographies $X course, compared this a for loss international cash quarter the invest in and North support and ATR of
spend time significant with about I want some ATR, are we We the and application milestones have opportunity our recently achieved. about and DrugSorb the talking excited to
Europe approved there in the in First, for I Union, to the are United that Brilinta. emphasize want or reversal of with therapies exception Canada States, agents the no or or cleared CytoSorb European
this reduce on purification ticagrelor or the investigational Brilinta has hospital artery application. by device that is known FDA Brilinta, coronary or in perioperative otherwise in ATR patients severity thinner, remove to commonly name blood sometimes designed DrugSorb medical who more our or syndrome. attack its designation are surgery. called blood is Brilinta, bypass an to heart device is patients brand suffering for a of bleeding the undergoing the graft aspirin in super to CABG called acute coronary DrugSorb granted a frequently administered breakthrough ATR
potentially In enjoys share, while in coronary syndrome said, Brilinta United XX% is surgery That natural washout to share of elimination heart Brilinta, by they the CABG Canada, days X States, of open patients because X restore blood bleeding near are stent, heart acute risk current market treatment surgery flow the Brilinta market the dominance of protocols. attack for from muscle, drug. surgery blood and use perioperative estimated delay eligible coronary serious will of of to a if the thinner, in an to the recommend high with the require guidelines or growing exclusive fatal often or for to allow not the heart
approach fold. this with The several problem is
patient death such the coronary heart while a because waiting. of as is blocked, exposing First, risk the is artery having the sudden attack them complications still still to
to significant depending can unstable the lead washout. patient they're waiting where Second, costs how is and to on waiting
slide, For XXXX example, the board below from room you this data patient Cleveland and on can price see charges Clinic published on alone.
ward a bed day, $X,XXX ICU day. $X,XXX $X,XXX Just and about a the a wait day step-down a about while is monitored a to is still bed an ICU in cardiac costs $X,XXX
that efficiency. endpoint the the in ATR hospital of surgery waiting This evaluated safety in within And randomized Board, safety of patients based Monitoring bleeding Brilinta the the U.S. to the perioperative of valuable Safety of and impacts led X trial DrugSorb XXX-patient met. used resources The study the efficacy discontinuation. hospital the and bed hospital that to and multicenter severity cardiac primary evaluation STAR-T the controlled, principal finally, Canadian and consumes was of reduce when trial Data of days concluded investigators upon independent double-blinded the
the population, met severe population. efficacy in was met the isolated importantly, was not endpoint Although the the primary all-comer endpoint of surgery bleeding study the in CABG
only bleed. the intraoperative NNT to was patients the a in than two, population, severity XX-hour major treat That represented drainage which favorable have associated Analyst with: Furthermore, number profile. with replay X data perioperative in definition prevent these at be chest an ATR were bleed; bleeding grade more reduced where the of with or can ATR XX% found you by Day presented CABG earnings major be Investor to presentation. was and our KOL needed people of use either one, the volume; universal the that would be of to isolated X found benefit-to-risk tube prevent means one event can A and overall or study, treat an the in able bleeding to https://lifescievents.com/event/cytosorbents/. to DrugSorb link therapy of three, DrugSorb This
although yet is our investigational conclusions principal of U.S. ATR and represent were under the and device investigators is FDA an medical reviewed this now that approved. note the The Health cleared yet the in review. study or Canada, opinion not the or slide DrugSorb not by and applications the on are of We Canada
substantive and which initiated the application, our in expedite for for is have randomized October and review XX marketing Novo this controlled which device is Canadian Based as on medical review trial, De to FDA our of breakthrough from an our upon STAR-T the data we they FDA Notably, priority application U.S. application September ATR, for our subsequently to DrugSorb eligible review this of application. designated accepted submitted pivotal intended device year, process.
We expect an XXXX. FDA in decision
on we our Secondly, certification Device certification the license application our medical Program on submitted Medical received day. of device November Audit this Canada and Health MDSAP or year, X Single same to
filing for significant MDL a the single Canada, well. regulatory successful medical program our States, management application but milestone Health certifies Australia that device for Japan Our of regulatory and CytoSorbents not standard audit to or MDSAP is with requirements our as quality Canada. system the only a Brazil, prerequisite United the and of MDSAP license and is a The certification compliance
consultants This certification body their addition, extremely a helped inspections own and work for the trial In clinicians, years external MDSAP starting slide of accepts team, dedicated with of STAR-T our agency proud of our substitute of as number achieve highlights U.S. and tremendous the these collaborators milestones. reports of major and I'm the initiation clinical if to who ago, audit a CytoSorbents a required. FDA culmination
We within an patients conference in in at or supportive undergoing this surgery patients on highlighting CABG supplementary Patients from generally CABG. comparable performance of X XXX by the often we the minimum dose. to international the in trial have real-world As settings. a in May Registry washout and STAR This STAR-T period, of favorable STAR-T data average impractical were Registry STAR in is of submission the additional XX.X said, early Canada in Health their also included benefit recommended in submissions, is undergoing system presented real-world hours in sooner to our results guideline of significantly than CABG show after surgery the year, technology I ticagrelor believe those is discontinuation. the last had ticagrelor supported an to DrugSorb EuroPCR XX-hour ticagrelor profile that our ATR the the Brilinta our days our data of risk of mentioned, FDA our trial. again That which
our treatments treated our the the patients lower taken in had surgery Brilinta patients that perioperative Patients last those there XX% severe trial. to in to that supportive last to compared dose technology a of XXX-patient not. in real-world reported from rates to XX the was patients was XXX of reported without bleeding those reduction CABG using within has are registry those on benefit the our than was by compared European CABG isolated additional results XX ticagrelor bleeding was were CABG that Registry registry. And in an of observed hours E-CABG the substantially the These in the what of that the Brilinta, -- XX within STAR-T technology multinational XX% technology. with in recorded bleeding surgery, bleeding and recorded reduction drawn the were undergoing When dose underwent severe hours of when in E-CABG on data STAR
treatment and timely be the and to care of in potential relevant of markets. improve the surgery and enabling, believe Health a Brilinta hospital DrugSorb while high CABG of Canadian eliminating again, markets a by This the Because delays additional to has consume patients to surgery Canada U.S. enjoys risk of win-win-win is that availability safe very attack due proposition DrugSorb all expose We future patients in ATR value the clearance these resources. heart requiring valuable this, potential market the share ATR or to standard FDA around. could
sudden the reduce has to minimize complications death. and definitive surgery serious bleeding as avoid waiting -- may importantly, it of patients, to and delays complications. such perioperative For potential
For the of utilization in quality resource costly reduces to and complications, help and drug the surgeons, streamline protect revenue surgical workflow, need direct and outcomes it generation who profitable change scheduling are hospitals, surgeries. for not of in for And to patients there is cardiac the by control. washout their rating reducing surgeon's no bleeding avoiding surgeon's complications may by that own the it and
that in as Brilinta, TAM transform believe market growing surgery share and reversible Brilinta syndromes in a availability We dominant total mentioned and Canada is States. acute standard addressable with to orally already the has current the patients an becomes in currently million. ATR potential a makes North in the drug. enjoys This Brilinta expected grow anti-platelet market generic CABG $XXX dominance million North to with well $XXX over coronary potential only ATR Brilinta. once DrugSorb administered The the of America the I Brilinta treated before, DrugSorb exceeds American on of ATR care estimated United patients undergoing DrugSorb in
oral ATR the market broadening like total cardiac pump to addressable blood billion. categories, blood inhibitors and ATR like Pradaxa, like of an and billion surgeries, expansion label $X OB/GYN, these that Eliquis including agents. orthopedic, in can thrombin other non-cardiac to CABG or use direct anticoagulants all-in-one for direct surgeries further the the include could the We off estimate other make DrugSorb thinners that And $X to expand with countermeasure DrugSorb thinner remove to and types Xarelto of surgery vascular surgeries potential non-CABG
years large markets experience certainly have and of for assured launch. leverage we had our core are this to American actively manufacturing experience preparing these commercialization markets, and Although North in are that expected be our international both
registry, of and shock, real-world outcomes rhabdomyolysis and patterns patients with usage data from used of sites treated patients ARDS closely at was for CytoSorb. caused to or care Spain, EACTAIC example, ESICM evidence COSMOS Medicine, Italy where by the septic of continue ] Society and usage of European real-world clinical trauma, presented muscle patterns across for treatment the or CytoSorb. The conference range At failure, indications, Intensive CytoSorb clinical outcomes We and acute-on-chronic which liver a we the analysis cardiogenic [ Care including, critical Germany, analyze in included invest Conference, others. XX in the acute tracks encouraging XXX diverse and shock, International
in in in that indications lactate, These rates with underscore We parameters, predicted to lung function key balance, mortality crucial outcomes were in and CytoSorb's utility significant use baseline, shock as reductions of clinical patients. overall the was standard the markers to lower improve rates Compared treatment for improved fluid standardized improvements and care CytoSorb critical vasopressin myoglobin than therapy importantly, care improvement with mortality reductions norepinephrine. potential significant to an critical clinical treatment reversal, the including scores. associated creatinine, to significantly the with data believe addition across for these requirement such led improved
quarter, with of pump or allowing mentioned, conduct trial a complexity of remains our treatment the periods last through machine. many received CytoSorb end is for the these we growth early to launched devices pump, without hemoperfusion us PuriFi machines. with been Innovation a key And priority easy-to-use demo quarter, which of have Approximately us. dialysis the blood an XX as can we place support that
and to range continue feedback enabling to We range course, system applications help and, broad positive technology broad drive of sales across that easy-to-use a from increased CytoSorb users geographies. of in demand be our a will cartridges receive of expect for initial this an of
a have we we in simple value So believe proposition. summary, and compelling
solid, progress critical and operational towards we Our surgery margin expansion are and and international flow efficiencies, business achieving care breakeven. steady cardiac cash is making
we would Canada growth. U.S. next could our Canadian company, large our enter Now us that believe FDA completed, allowing well markets, us catalytic expect which be the important regulatory submissions XXXX decisions to for Health position U.S. phase with we and and of from key in regulatory and to
With said, now me let Officer, go Mariani, Pete? over financial over turn that it to Pete Chief Financial to our highlights.
